Evidence map›Paper›PMID 41362667›Full record

ReviewMethodsX2025

Artificial inteligence and datasets for leukemia diagnosis: A scoping review of machine lerning and deep learning approaches.

Ashwini Tande, Renuka Mane

Abstract readReview
In one paragraph

Review in MethodsX, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ashwini TandeDepartment of Computer Engineering and Technology, Dr. Vishwanath Karad MIT World Peace University, Pune, India.
Renuka ManeDepartment of Computer Engineering and Technology, Dr. Vishwanath Karad MIT World Peace University, Pune, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leukemia is the cancerous disease of the blood and the bone marrow that causes excessive proliferation of abnormal white blood cells, if detected too late, it can lead to potentially fatal consequences. Peripheral blood smear examinations and bone marrow biopsy are example of conventional diagnostic techniques that are invasive, time-consuming and subject to human variability. Recent advances in artificial intelligence (AI) particularly in the areas of Machine Learning (ML) and Deep Learning (DL)offer encouraging answers by making it possible to detect and classify leukemia using automated, effective and precise techniques. With an emphasis on image-based techniques based on publicly available datasets such as ALL-IDB, C-NMC, AML_Cytomorphology_LMU, SN-AM and CPTAC-AML, this paper reviews the most recent research on Machine Learning and Deep Learning approaches includes Convolutional Neural Networks (CNNS), ResNet, DenseNet, MobileNet and ensemble models for leukemia diagnosis. The survey highlights some of the most significant issues, such as dataset imbalance, stain variability, lack of standard annotations and limited clinical validation. The paper also discusses research gap and future initiatives including Explainable AI, lightweight deployment models, clinically reliable diagnostic system and hierarchical classification framework aligned with WHO 2022 classification standards.

Indexed as

Deep learningLeukemia diagnosisPeripheral blood smearWHO 2022 Classification

Identifiers

PMID41362667
PMCPMC12681519

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.